// App-Quantinova.ai

1612 : Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

Researchers

Presenter

  • Anthony D Ho

Principal Investigators

  • Evelyn Kuhnt

  • Michael Pfreundschuh

  • Marek Trneny

  • Michael Rieger

  • Anders Osterborg

  • Ruth Pettengell

  • Robert Stevens

  • Devinder S Gill

  • Jan Walewski

  • Markus Loeffler

Medical Centers

  • Karolinska Institutet, Karolinska University Hospital and SweBCG, Stockholm, Sweden

  • Department of Lymphoid Diseases, The Maria Sklodowska-Curie Memorial Institute and Centre of Oncology, Warsaw, Poland

  • Dept. of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

  • st Department of Internal Medicine- Dept. of Hematology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic

  • Institute for Medical Informatics, Statistics and Epidemology, Leipzig University, Leipzig, Germany

  • Clinical Trial Centre Leipzig, University of Leipzig, Leipzig, Germany

  • Onkologische Praxis, Darmstadt, Germany

  • Grand River Cancer Centre, Kitchener, ON, Canada,

  • Infection and Immunity Division of Clinical Sciences,St. Georges University of London, London, United Kingdom

  • Innere Medizin I, Universitaetsklinikum des Saarlandes, Homburg/Saar, Germany

  • Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia

Locations

  • Czech Republic

  • Canada

  • Poland

  • Germany

  • United Kingdom

  • Australia

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • open label

  • randomized

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved